Advanced Search

Submit Manuscript

Volume 35, No 1, Jan 2025

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 35 Issue 1, January 2025: 5-6

RESEARCH HIGHLIGHTS

LKB1 inactivation unleashes prostate cancer lineage plasticity

Shaghayegh Nouruzi1,2 , Amina Zoubeidi1,2,*

1Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
2Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
Correspondence: Amina Zoubeidi(azoubeidi@prostatecentre.com)

While it is well established that androgen receptor pathway inhibition leads to the development of double-negative prostate cancer (DNPC), the mechanisms underlying this cell fate decision remain unclear. In a recent study published in Cell Research, Li et al. identified that LKB1 inactivation supports the development of DNPC through metabolic and epigenetic rewiring, highlighting DNA hypomethylation as a vulnerability and TET2/3 as potential therapeutic targets.


https://doi.org/10.1038/s41422-024-01030-2

FULL TEXT | PDF

Browse 105